The use of Non-steroidal anti-inflammatory drugs as well as the infecting agent H Pylori has been attributed as the prominent common etiological factor for peptic ulcers in patients. Distinguishing proof of Helicobacter pylori as the essential etiologic factor in the improvement of peptic ulcer illness and the perception that the frequency of H. pylori increments with age have brought up the issue of a potential synergistic connection between the presence of H. pylori contamination and NSAID use in the improvement of treatment in gastroenterology. Both H.Pylori and NSAIDs have, nevertheless, been appeared to affect the creation rate and the nature of gastric cyclic AMP, the bodily fluid layer, mucosal prostaglandins, blood stream, and platelet-activating factor.  Therefore, it is necessary to determine the risk factors such as age and history of peptic ulcers of the patient prior to prescribing. A co-prescription may be important to reduce the risk of peptic ulcers in patients of high risk. Since H.Pylori infection remains the world's most common chronic bacterial infection, it has been suggested that the establishment of a synergistic or additive effect of H.Pylori infection and NSAID use in the development of peptic ulcer is of great clinical importance as eradication of the bacterium is likely to reduce the risk of upper gastrointestinal complications in infected NSAID users. The prevention and overcoming of NSAIDS induced peptic ulcer and H Pylori induced peptic ulcer is embedded in the thorough understanding and assessment of pathophysiology and other underlying causes in each individual patient. There are wide range of studies that emphasize on the various methods of overcoming these conditions as well as understanding the co factors for the risk of ulcer. The main aim of the treatment is to protect the gastric mucosal layer from further eroding away and heal the mucosal ulcer as soon as possible to avoid further complications.